Zai Lab Limited (ZLAB)
| Bid | 35.21 |
| Market Cap | 394.4M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | -14.01 |
| Forward PE | -15.21 |
| Analyst | Buy |
| Ask | 38 |
| Volume | 891,228 |
| Avg. Volume (20D) | 924,945 |
| Open | 36.25 |
| Previous Close | 37.29 |
| Day's Range | 35.33 - 36.48 |
| 52-Week Range | 13.48 - 39.77 |
| Beta | 1.07 |
About ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and ...
Analyst Forecast
According to 4 analyst ratings, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is $51, which is an increase of 40.01% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War RisksZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approval...
1 month ago · businesswire.com
Zai Lab Announces Participation in Investor Conferences in March 2025SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor...
